Vascular Endothelial Growth Factor Receptor-2

Download PDF

Recent Publications on Vascular Endothelial Growth Factor Receptor-2:
Endothelial and Myogenic Differentiation of Hematopoietic Progenitor Cells in Inflammatory Myopathies. Incorporation of circulating hematopoietic progenitor cells (HPCs) into...	4th July, 2008	From the Department of Blood Group Serology and Transfusion Medicine (DH,	J Neuropathol Exp Neurol. 2008 Jun 24;. DOI Direct Link
[Mechanisms of impaired perfusion recovery in type 1 diabetic mouse] OBJECTIVE: To investigate the perfusion restoration of type 1 diabetic...	4th July, 2008	Department of Vascular Surgery, PUMC Hospital, CAMS and PUMC, Beijing	Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2007 Dec;29(6):742-6.
Molecular control of lymphatic metastasis. The metastatic spread of tumor cells is the most lethal aspect of cancer...	4th July, 2008	Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria	Ann N Y Acad Sci. 2008;1131:225-34. DOI Direct Link
Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2-Derived Epitope in Association with HLA-DR. PURPOSE: Given the multiple escape mechanisms of tumor cells,...	3rd July, 2008	Authors' Affiliations: Division of Medical Biotechnology,	Clin Cancer Res. 2008 Jul 1;14(13):4306-15. DOI Direct Link
Erythropoietin increases the motility of human bone marrow multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Cell therapy has been extensively studied as an approach to repair damage...	2nd July, 2008	Hanyang University, Neurology, Seoul, Korea, Republic of;	Stem Cells Dev. 2008 Jun 30;. DOI Direct Link
→View more research publications.

BioNews Results for Vascular Endothelial Growth Factor Receptor-2:
Crohn's disease: beyond antagonists of tumour necrosis factor	Lancet:  Jul 4 2008 12:44AM Matching: vascular endothelial growth factor receptor 2
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Cal	Journal of the American Medical Association:  Jun 10 2008 9:35PM Matching: vascular endothelial growth factor receptor 2
UPDATE: Erbitux, Avastin Combo No Benefit In Colon Cancer	CNN Money:  Jun 1 2008 4:43AM Matching: vascular endothelial growth factor receptor 2
Cyclacel Pharmaceuticals Presents Insights Into The Mechanisms Of Its Cell Cycle Inhibitor Drugs	BioPortfolio:  May 19 2008 12:25PM Matching: vascular endothelial growth factor receptor 2
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies	PharmCast:  May 16 2008 4:13AM Matching: vascular endothelial growth factor receptor 2
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

Vascular Endothelial Growth Factor Receptor-2 Clinical Trials:
Fibrin Melanoma Axillary Node Study in Patients With Melanoma	Melanoma Intervention: Drug: Fibrin Sealant
Study of XL184 in Adults With Glioblastoma Multiforme	Glioblastoma Multiforme
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib	Carcinoma, Non-Small-Cell Lung
Study of XL647 Administered Orally Daily to Patients With Solid Tumors	Cancer Intervention: Drug: XL647
Vandetanib in Treating Patients With Von Hippel-Lindau Syndrome and Kidney Tumors	Kidney Cancer;   Von Hippel-Lindau Syndrome
→View more trials.

Vascular Endothelial Growth Factor Receptor-2 Patents:
US Patent No.	Title
6756055	Cationic lipid compositions targeting angiogenic endothelial cells
6867348	Methods and compositions for screening for angiogenesis modulating compounds
6869962	Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
6887468	Antibody kits for selectively inhibiting VEGF
6897207	Azaindoles
→View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Vascular Endothelial Growth Factor Receptor-2 scientists - we have details of around 177 individuals working on Vascular Endothelial Growth Factor Receptor-2 .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.